Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. May 28, 2024; 15(3): 90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Published online May 28, 2024. doi: 10.4292/wjgpt.v15.i3.90757
Symptom relief (% vs W0) | W2 (%) | W4 (%) |
Constipation | ||
Unchanged | 58 | 54 |
Relief (very much, considerable) | 42 (27, 15) | 46 (37, 9) |
Diarrhea | ||
Unchanged | 44 | 42 |
Relief (very much, considerable) | 46 (42, 14) | 58 (39, 19) |
Defecatory disorders | ||
Unchanged | 56 | 58 |
Relief (very much, considerable) | 44 (36, 8) | 42 (31, 11) |
- Citation: Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
- URL: https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i3.90757